Objective To assess the costs and benefits of two algorithms for cervical cancer screening in
Belgium (1) high-risk human papillomavirus (HR-HPV) primary screening and (2) HR-HPV …

Background: New screening technologies and vaccination against human papillomavirus
(HPV), the necessary cause of cervical cancer, may impact optimal approaches to prevent …

Please cite this paper as: van Rosmalen J, de Kok I, van Ballegooijen M. Cost‐effectiveness
of cervical cancer screening: cytology versus human papillomavirus DNA testing. BJOG …

Objective We aim to compare the cost‐effectiveness of the old cytology programme with the
new high‐risk human papillomavirus (hrHPV) screening programme, using performance …

Background Sweden revised their cervical cancer screening program in 2017 to include
cytology-based screening for women aged 23–29 years and primary human papillomavirus …

Human papillomavirus (HPV) testing is replacing cytological screening for cervical cancer.
Our aim was to assess the expected benefits and harms of different cervical screening …

Objective: Population screening programmes must make good use of resources for the
health system and users. To evaluate impacts of the type of diagnostic test in the new French …

Background Vaccination against the oncogenic human papillomavirus (HPV) types 16 and
18 will reduce the prevalence of these types, thereby also reducing cervical cancer risk in …

Abstract Objective Eastern European countries are contemplating to introduce the high-risk
Human Papillomavirus (HPV)-test as the primary screening test for their cervical cancer …

Introduction Cervical cancer (CC) is a type of cancer with poor prognosis when diagnosed in
advanced stage with a big socioeconomic burden. The incidence rates have wide variations …